Yuhan Corporation

Johnson & Johnson announced positive Phase 3 MARIPOSA study results for RYBREVANT® plus LAZCLUZE™, showing improved overall survival in EGFR-mutated NSCLC patients, exceeding one year over standard care. The chemotherapy-free regimen marks a significant advancement in first-line treatment, offering hope for extended life expectancy.

Johnson & Johnson announced positive Phase 3 MARIPOSA study results for RYBREVANT® plus LAZCLUZE™, showing a significant overall survival improvement over a year for EGFR-mutated NSCLC patients, surpassing the current standard care osimertinib. This chemotherapy-free regimen marks a breakthrough in first-line treatment, offering hope for extended life expectancy.

Johnson & Johnson announced positive Phase 3 MARIPOSA study results for RYBREVANT® plus LAZCLUZE™, showing a significant improvement in overall survival for EGFR-mutated NSCLC patients, exceeding one year over the current standard of care. This chemotherapy-free regimen marks a pivotal advancement in first-line treatment, offering hope for extended life expectancy.

Johnson & Johnson announced that RYBREVANT® plus LAZCLUZE™ significantly improves overall survival in EGFR-mutated NSCLC patients, exceeding one year over current standard care. This chemotherapy-free regimen marks a breakthrough in first-line treatment, offering hope for extended life expectancy and better outcomes.

Johnson & Johnson announced that RYBREVANT® plus LAZCLUZE™ significantly improves overall survival in EGFR-mutated NSCLC patients, exceeding one year over current standard care. This chemotherapy-free regimen marks a breakthrough in first-line treatment, offering hope for extended life expectancy.

Johnson & Johnson announced that the combination of RYBREVANT® and LAZCLUZE™ significantly improves overall survival (OS) in EGFR-mutated NSCLC patients, exceeding one year over the current standard care. This chemotherapy-free regimen marks a breakthrough in first-line treatment, offering hope for extended life expectancy.

The FDA approved 50 new drugs in 2023, including contributions from South Korea's Hugel and Yuhan Corporation. Notable approvals include treatments for NASH and schizophrenia. Cancer drugs led with 15 approvals. South Korea's FDA-approved drugs highlight its growing role in global pharmaceutical innovation.

Yuhan Corporation's lung cancer drug Leclaza, combined with Rybrevant, received European approval for treating NSCLC with specific EGFR mutations, offering a potential new first-line standard treatment.

Yuhan Corporation's anti-cancer drug lazertinib, approved in Europe, marks the first Korean cancer drug approved there after U.S. approval. It's part of a combination therapy with RYBREVANT for NSCLC, backed by Phase 3 MARIPOSA study results. Yuhan receives a USD 30 million milestone payment from Janssen.